vorinostat has been researched along with Acquired Immune Deficiency Syndrome in 2 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Tamoxifen did not enhance vorinostat-induced HIV transcription (between-arm ratio, 0." | 3.11 | Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. ( Aga, E; Archin, N; Bosch, RJ; Chomont, N; Connick, E; Coxen, K; Deeks, S; Dobrowolski, C; Ehui, L; Gandhi, M; Gandhi, RT; Giguel, F; Godfrey, C; Hosey, L; Howell, BJ; Karn, J; Kuritzkes, DR; Ma, Q; Morse, GD; Scully, EP; Sieg, SF; Squires, KE; Starr, K; Tsibris, A; Wu, G, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scully, EP | 1 |
| Aga, E | 1 |
| Tsibris, A | 1 |
| Archin, N | 1 |
| Starr, K | 1 |
| Ma, Q | 1 |
| Morse, GD | 1 |
| Squires, KE | 1 |
| Howell, BJ | 1 |
| Wu, G | 1 |
| Hosey, L | 1 |
| Sieg, SF | 1 |
| Ehui, L | 1 |
| Giguel, F | 1 |
| Coxen, K | 1 |
| Dobrowolski, C | 1 |
| Gandhi, M | 1 |
| Deeks, S | 1 |
| Chomont, N | 1 |
| Connick, E | 1 |
| Godfrey, C | 1 |
| Karn, J | 1 |
| Kuritzkes, DR | 1 |
| Bosch, RJ | 1 |
| Gandhi, RT | 1 |
| Al-Jabri, AA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Selective Estrogen Receptor Modulators to Enhance the Efficacy of Viral Reactivation With Histone Deacetylase Inhibitors[NCT03382834] | Phase 2 | 31 participants (Actual) | Interventional | 2018-04-26 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Cell-associated HIV-1 RNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38
| Intervention | log10 copies/million CD4 cells (Mean) |
|---|---|
| Arm A: Tamoxifen + Vorinostat | 0.06 |
| Arm B: Vorinostat Alone | 0.17 |
Baseline is defined as the average of the pre-entry and entry values. Change was calculated as the value of Total HIV-1 DNA on Day 38 (5 hours post vorinostat) minus the value at baseline. (NCT03382834)
Timeframe: Pre-entry, entry, and Day 38
| Intervention | log10 copies/million CD4 cells (Mean) |
|---|---|
| Arm A: Tamoxifen + Vorinostat | 0 |
| Arm B: Vorinostat Alone | -0.04 |
Proportion of participants with new Grade 3 or greater adverse events that are considered definitely, probably, or possibly related to study treatment (as judged by the core protocol team). The DAIDS AE Grading Table (corrected Version 2.1, July 2017) was used. (NCT03382834)
Timeframe: Measured from study entry through Day 65
| Intervention | proportion of participants (Number) |
|---|---|
| Arm A: Tamoxifen + Vorinostat | 0 |
| Arm B: Vorinostat Alone | 0 |
Number of participants with HIV-1 RNA levels measured by single copy assay (SCA) greater or equal to the lower limit of quantification (LOQ). The lower limit of quantification for this study was 0.47 copies/mL. (NCT03382834)
Timeframe: Pre-entry, entry, Day 28, Day 35, Day 38 (5 hours post vorinostat), Day 45, Day 65
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Pre-entry SCA >= LOQ | Entry SCA >=LOQ | Day 28 SCA >=LOQ | Day 35 SCA >=LOQ | Day 38 SCA >=LOQ | Day 45 SCA >=LOQ | Day 65 SCA >=LOQ | |
| Arm A: Tamoxifen + Vorinostat | 10 | 9 | 11 | 11 | 7 | 9 | 10 |
| Arm B: Vorinostat Alone | 6 | 3 | 4 | 5 | 5 | 4 | 5 |
1 trial available for vorinostat and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial.
Topics: Acquired Immunodeficiency Syndrome; CD4-Positive T-Lymphocytes; DNA; Estrogen Receptor alpha; Female | 2022 |
1 other study available for vorinostat and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Forcing the enemy to come out and surrender: a strategy for an AIDS cure.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Depsipep | 2015 |